ERT signs definitive agreement to acquire PHT

ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation (PHT), the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced today that they have signed a definitive agreement under which ERT will acquire PHT. Financial terms of the transaction were not disclosed.

The transaction combines the flexible eCOA platform and world-class customer service of PHT with the leading clinical trial technology and service offerings of ERT, creating the most innovative and comprehensive solution for patient endpoint collection and data analytics for global clinical trials.

"We are thrilled to announce this strategic merger with PHT," said Jim Corrigan, President and CEO of ERT. "This combination is about better serving our customers and delivering solutions to support the tremendous growth projected for the eCOA industry. By joining forces we are creating a truly innovative eCOA offering with global reach across therapeutic areas. Additionally, the transaction accelerates our strategy of innovating better health by becoming the software-enabled solution provider of choice; supporting clinical trials from early phase through regulatory submission and post-market research; and adding to our existing eCOA, respiratory, cardiac and data analytics portfolio."

"This is a compelling combination that brings together two industry pioneers committed to using technology to transform clinical research and help bring new therapies to market," said Philip Lee, President and CEO of PHT. "Our two companies share the same entrepreneurial drive, culture of innovation and unwavering focus on customer success and together we will be very well positioned to deliver best-in-class solutions to support patient-centric data collection in clinical trials."

The combined company will have an increased global footprint throughout North America, Europe and in Asia, while serving all phases of clinical research for small and mid-sized biopharma to CROs and large pharmaceutical companies, including the top 30 pharmaceutical companies in the world. The combined scientific and regulatory expertise as well as the deep technical and operational teams in place will continue to bring innovative, patient-centric solutions to the clinical research industry.

The transaction is subject to regulatory review and is expected to close within the next several weeks.